Australia markets closed

Cryo-Cell International, Inc. (CCEL)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
12.00-0.38 (-3.07%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close12.38
Open12.36
Bid0.00 x 1800
Ask0.00 x 1100
Day's range11.78 - 12.40
52-week range7.33 - 14.16
Volume4,024
Avg. volume3,614
Market cap102.356M
Beta (5Y monthly)0.33
PE ratio (TTM)25.00
EPS (TTM)0.48
Earnings date22 Feb 2022 - 28 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Cord Blood Banking Leader Cryo-Cell Announces Its Intent to Advance Clinical Trials

    OLDSMAR, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announces further plans for its newly developed Institute for Cellular Therapies. As a result of the exclusive license agreement signed with Duke University on February 26, 2021, Cryo-Cell acquired exclusive commercial rights to a range of intellectual property assets and FDA regu

  • GlobeNewswire

    Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2021 Financial Results

    OLDSMAR, Fla., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2021. Financial Results RevenueConsolidated revenues for the third quarter of fiscal 2021 were $7.5 million compared to $8.1 million for the third quarter of fiscal 2020. The revenues for the third quarter of fiscal 2

  • GlobeNewswire

    Cryo-Cell International Announces Changes To Its Board of Directors

    MIAMI, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (Nasdaq:CCEL), the leader in cord blood and cord tissue cryopreservation services, announces the appointment of Mr. Mark Portnoy and Mr. Daniel Mizrahi to the Company’s Board of Directors, replacing Mr. George Gaines and Jonathan Wheeler, M.D., who have resigned in their capacity as Directors. Mr. Gaines has chosen to retire while Dr. Wheeler has resigned for health reasons. The Board of Directors voted unanimously in favor